{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:25:16Z","timestamp":1780507516344,"version":"3.54.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI1400708"],"award-info":[{"award-number":["PI1400708"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["DTS15\/00171"],"award-info":[{"award-number":["DTS15\/00171"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virus Research"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.virusres.2015.12.019","type":"journal-article","created":{"date-parts":[[2015,12,29]],"date-time":"2015-12-29T03:16:04Z","timestamp":1451358964000},"page":"224-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus"],"prefix":"10.1016","volume":"213","author":[{"given":"Joanna","family":"Luczkowiak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7410-9450","authenticated-orcid":false,"given":"Jos\u00e9 R.","family":"Arribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Jim\u00e9nez-Yuste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"de la Calle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2544-3492","authenticated-orcid":false,"given":"Aurora","family":"Viejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3724-4861","authenticated-orcid":false,"given":"Rafael","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.virusres.2015.12.019_bib0005","doi-asserted-by":"crossref","first-page":"5998","DOI":"10.1016\/j.vaccine.2009.07.079","article-title":"Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses","volume":"27","author":"Alberini","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.virusres.2015.12.019_bib0010","doi-asserted-by":"crossref","first-page":"6841","DOI":"10.1128\/JVI.76.13.6841-6844.2002","article-title":"C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans","volume":"76","author":"Alvarez","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2015.12.019_bib0015","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1056\/NEJMoa1404505","article-title":"Emergence of Zaire Ebola virus disease in Guinea","volume":"371","author":"Baize","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virusres.2015.12.019_bib0020","doi-asserted-by":"crossref","first-page":"e1395","DOI":"10.1371\/journal.pntd.0001395","article-title":"Ebola virus glycoprotein needs an additional trigger, beyond proteolytic priming for membrane fusion","volume":"5","author":"Bale","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.virusres.2015.12.019_bib0025","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1086\/382658","article-title":"In vitro evaluation of cyanovirin-N antiviral activity, by use of lentiviral vectors pseudotyped with filovirus envelope glycoproteins","volume":"189","author":"Barrientos","year":"2004","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virusres.2015.12.019_bib0030","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1128\/JVI.05708-11","article-title":"Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change","volume":"86","author":"Brecher","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2015.12.019_bib0035","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nrd984","article-title":"Therapeutic antibodies for human diseases at the dawn of the twenty-first century","volume":"2","author":"Brekke","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.virusres.2015.12.019_bib0040","doi-asserted-by":"crossref","first-page":"e60838","DOI":"10.1371\/journal.pone.0060838","article-title":"Lectin-dependent enhancement of Ebola virus infection via soluble and transmembrane C-type lectin receptors","volume":"8","author":"Brudner","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.virusres.2015.12.019_bib0045","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1006\/viro.1995.1016","article-title":"Vpr is required for efficient replication of Human-Immuno-Deficiency-Virus Type-1 in mononuclear phagocytes","volume":"206","author":"Connor","year":"1995","journal-title":"Virology"},{"key":"10.1016\/j.virusres.2015.12.019_bib0050","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1128\/JVI.75.5.2224-2234.2001","article-title":"Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian\/human immunodeficiency virus infection in pigtailed macaques","volume":"75","author":"Cho","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2015.12.019_bib0055","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1126\/science.1259657","article-title":"Genomic surveillance elucidates Ebola virus origin and transmission during theoutbreak","volume":"345","author":"Gire","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.virusres.2015.12.019_bib0060","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial","volume":"386","author":"Henao-Restrepo","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.virusres.2015.12.019_bib0065","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jviromet.2009.04.037","article-title":"A neutralization test for specific detection of Nipah virus antibodies using pseudotyped vesicular stomatitis virus expressing green fluorescent protein","volume":"160","author":"Kaku","year":"2009","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.virusres.2015.12.019_bib0070","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1089\/08892220152741414","article-title":"Development of a safe and rapid neutralization assay using murine leukemia virus pseudotyped with HIV type 1 envelope glycoprotein lacking the cytoplasmic domain","volume":"17","author":"Kim","year":"2001","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.virusres.2015.12.019_bib0075","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3201\/eid2103.141838","article-title":"Treatment of Ebola virus infection with antibodies from reconvalescent donors","volume":"21","author":"Kreil","year":"2015","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.virusres.2015.12.019_bib0080","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa1411677","article-title":"A case of severe Ebola virus infection complicated by gram-negative septicemia","volume":"371","author":"Kreuels","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virusres.2015.12.019_bib0085","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.3390\/v6114760","article-title":"Nomenclature- and database-compatible names for the two Ebola virus variants that emerged in Guinea and the Democratic Republic of the Congo in 2014","volume":"6","author":"Kuhn","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.virusres.2015.12.019_bib0090","article-title":"Chimpanzee adenovirus vector ebola vaccine\u2014preliminary report","author":"Ledgerwood","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virusres.2015.12.019_bib0095","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature07082","article-title":"Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor","volume":"454","author":"Lee","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.virusres.2015.12.019_bib0100","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1128\/JVI.73.7.6024-6030.1999","article-title":"Ebola virus can be effectively neutralized by antibody produced in natural human infection","volume":"73","author":"Maruyama","year":"1999","journal-title":"J.Virol."},{"key":"10.1016\/j.virusres.2015.12.019_bib0105","article-title":"Vesicular stomatitis virus-based vaccines for prophylaxis and treatment of filovirus infections","volume":"S1","author":"Marzi","year":"2011","journal-title":"J. Bioterror Biodef."},{"key":"10.1016\/j.virusres.2015.12.019_bib0110","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1073\/pnas.1502619112","article-title":"Human Ebola virus infection results in substantial immune activation","volume":"112","author":"McElroy","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.virusres.2015.12.019_bib0115","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nature14428","article-title":"Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus","volume":"520","author":"Mire","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.virusres.2015.12.019_bib0120","doi-asserted-by":"crossref","first-page":"17182","DOI":"10.1073\/pnas.1414164111","article-title":"Structures of protective antibodies reveal sites of vulnerability on Ebola virus","volume":"111","author":"Murin","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.virusres.2015.12.019_bib0125","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature13777","article-title":"Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp","volume":"514","author":"Qiu","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.virusres.2015.12.019_bib0130","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ncomms2302","article-title":"Virus-like glycodendrinanoparticles displaying quasi-equivalent nested polyvalency upon glycoprotein platforms potently block viral infection","volume":"3","author":"Ribeiro-Viana","year":"2012","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virusres.2015.12.019_bib0135","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nm.3702","article-title":"Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge","volume":"20","author":"Stanley","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.virusres.2015.12.019_bib0140","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1371\/journal.pmed.0030177","article-title":"Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs","volume":"3","author":"Sullivan","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.virusres.2015.12.019_bib0145","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrmicro2129","article-title":"Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule","volume":"7","author":"Sullivan","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.virusres.2015.12.019_bib0150","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1128\/JVI.77.2.1069-1074.2003","article-title":"Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses","volume":"77","author":"Takada","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2015.12.019_bib0155","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3201\/eid1103.040906","article-title":"Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes","volume":"11","author":"Temperton","year":"2005","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.virusres.2015.12.019_bib0160","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1056\/NEJMoa1411100","article-title":"Ebola virus disease in West Africa-the first 9 months of the epidemic and forward projections","volume":"371","author":"WHO","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virusres.2015.12.019_bib0165","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1586\/1744666X.2014.908705","article-title":"Characterization of host immune responses in Ebola virus infections","volume":"10","author":"Wong","year":"2014","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"10.1016\/j.virusres.2015.12.019_bib0170","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1099\/vir.0.2008\/000349-0","article-title":"Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison","volume":"89","author":"Wright","year":"2008","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.virusres.2015.12.019_bib0175","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1126\/science.279.5353.1034","article-title":"Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins","volume":"279","author":"Yang","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.virusres.2015.12.019_bib0180","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/78654","article-title":"Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury","volume":"6","author":"Yang","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.virusres.2015.12.019_bib0185","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1016\/S0140-6736(15)60553-0","article-title":"Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"385","author":"Zhu","year":"2015","journal-title":"Lancet"}],"container-title":["Virus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170215301866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170215301866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T14:06:10Z","timestamp":1759154770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168170215301866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":37,"alternative-id":["S0168170215301866"],"URL":"https:\/\/doi.org\/10.1016\/j.virusres.2015.12.019","relation":{},"ISSN":["0168-1702"],"issn-type":[{"value":"0168-1702","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus","name":"articletitle","label":"Article Title"},{"value":"Virus Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virusres.2015.12.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}